Sagimet Biosciences entered two Russell indexes at the open of U.S. markets on June 29, 2026. The San Mateo, California company, which trades on Nasdaq as SGMT, announced that it had been added to the broad-market Russell 3000 and the small-cap Russell 2000 as part of the annual reconstitution.
The mechanics are set by FTSE Russell. Each June it ranks up to the 4,000 largest U.S. stocks by total market capitalization as of April 30. Membership in the Russell 3000 brings automatic placement in either the large-cap Russell 1000 or the small-cap Russell 2000, along with the matching growth and value style indexes. FTSE Russell decides membership mainly on objective size rankings and style attributes. In 2026 the Russell 3000 membership stays in place for half a year.
The company’s read
Sagimet is a clinical-stage biopharmaceutical company. It develops FASN inhibitors, drugs aimed at metabolic and fibrotic pathways that arise from an overproduction of the fatty acid palmitate. FASN regulates lipid synthesis and is implicated in acne, MASH and certain tumor types that depend on it.
Chief Executive David Happel tied the index news to the company’s year. “We believe inclusion in the Russell indexes reflects the meaningful progress Sagimet has made over the last year,” he said.
Acne and the Phase 3 plan
The lead program is denifanstat for moderate to severe acne. Sagimet plans to start a U.S. Phase 3 trial in the second half of 2026, and the study will include adolescents aged 12 and older.
Happel said that if approved, denifanstat “would be the first innovative oral treatment for acne vulgaris in patients aged 12 years and older in more than forty years.”
The company says it has the capital to fund its programs through 2028. That covers the data readout from the planned Phase 3 acne trial. “We look forward to the broader visibility that inclusion in the Russell indexes brings,” Happel said.
The announcement carries the usual forward-looking caveats. Sagimet noted that its plans depend on advancing candidates into and through clinical trials on schedule, on its relationship with Ascletis and the progress of that partner’s work on denifanstat, and on its estimates of capital needs and its ability to protect its intellectual property.
